Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25256802 | 0.91 | ALDH1A1 (0.46) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL6450266 | 0.88 | HPGD (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL27120710 | 0.87 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL21405187 | 0.85 | GPR119 (0.47) | HPGDRECQLEPHX1GPR119NR1H2 | |
| SCHEMBL21405190 | 0.85 | GPR119 (0.47) | HPGDRECQLEPHX1GPR119NR1H2 | |
| SCHEMBL25301539 | 0.84 | NR1H2 (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL25301424 | 0.83 | MEN1 (0.53) | HPGDEPHX1ALDH1A1NR1H2MAPT | |
| SCHEMBL12820311 | 0.83 | HPGD (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL6446543 | 0.82 | GPR119 (0.44) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL15203221 | 0.81 | HPGD (0.51) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115232108-B | SOS1 degradation agent and preparation method and application thereof | 领泰生物医药(绍兴)有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| CN-118510770-A | Fused heteroaryl hydroxamic acids as STING agonists | 比西切姆有限公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-114945560-B | GPR119 agonists | 卡尔优普公司 | 2024-08-13 | — | — | CN | disclosed |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | LEADINGTAC PHARMACEUTICAL (SHAOXING) CO., LTD. (CN) | 2024-08-08 | — | — | US | disclosed |
| US-20240217983-A1 | GPR119 AGONISTS | KALLYOPE, INC. | 2024-07-04 | — | — | US | disclosed |
| CN-118076595-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4328219-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Leadingtac Pharmaceutical Co. Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| EP-4320129-A1 | GPR119 AGONISTS | Kallyope, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006228-B2 | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140128368-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128368-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128368-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-05-08 | — | — | US | disclosed |
| US-6964974-B2 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1317432-A1 | PIPERIDINE DERIVATIVES FOR USE AS 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-11 | — | — | EP | disclosed |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | HOFFMANN-LA ROCHE INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002020483-A1 | PIPERIDINE DERIVATIVES FOR USE 2,3-OXIDOSQUALENE-LANOSTEROL CYCLASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261418-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SOS1, RAC1, RSU1 | HPGD 3600/4885RECQL 1329/4885EPHX1 544/4885 |
| US-20240217983-A1 | GPR119 AGONISTS | GPR119, GLP1R, GCGR | HPGD 1594/4885RECQL 4620/4885EPHX1 1614/4885 |
| US-20140128368-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | GPR119, GCGR, GPR27 | HPGD 940/4885RECQL 3133/4885EPHX1 1614/4885 |
| US-20240261417-A1 | SOS1 DEGRADING AGENT AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RAC1, SOS1, RSU1 | HPGD 2612/4885RECQL 1447/4885EPHX1 474/4885 |
| US-20020068753-A1 | 2,3-oxidosqualene-lanosterol cyclase inhibitors | CYP51A1, LSS, CYP46A1 | HPGD 43/4885RECQL 3404/4885EPHX1 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.